EA200601651A1 - Полиморфные формы трет-бутилового эфира аторвастатина и их использование в качестве промежуточных соединений для получения аторвастатина - Google Patents

Полиморфные формы трет-бутилового эфира аторвастатина и их использование в качестве промежуточных соединений для получения аторвастатина

Info

Publication number
EA200601651A1
EA200601651A1 EA200601651A EA200601651A EA200601651A1 EA 200601651 A1 EA200601651 A1 EA 200601651A1 EA 200601651 A EA200601651 A EA 200601651A EA 200601651 A EA200601651 A EA 200601651A EA 200601651 A1 EA200601651 A1 EA 200601651A1
Authority
EA
Eurasian Patent Office
Prior art keywords
atorvastatin
treat
butyl ether
intermediate compounds
polymorphic forms
Prior art date
Application number
EA200601651A
Other languages
English (en)
Other versions
EA010166B1 (ru
Inventor
Антон Стимац
Рок Зупет
Мария Грцман
Матей Смрколь
Рената Яксе
Original Assignee
Крка, Товарна Здравил, Д.Д., Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка, Товарна Здравил, Д.Д., Ново Место filed Critical Крка, Товарна Здравил, Д.Д., Ново Место
Publication of EA200601651A1 publication Critical patent/EA200601651A1/ru
Publication of EA010166B1 publication Critical patent/EA010166B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к кристаллическим формам 1 и 2 трет-бутилового эфира аторвастатина (формула (II)), способам их получения и превращения в геми-кальциевую соль аторвастатина с высокой степенью чистоты в некристаллической, в частности аморфной, форме.
EA200601651A 2004-04-09 2005-04-08 Полиморфные формы трет-бутилового эфира аторвастатина и их использование в качестве промежуточных соединений для получения аторвастатина EA010166B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400112A SI21745A (sl) 2004-04-09 2004-04-09 Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
PCT/EP2005/003733 WO2005097742A1 (en) 2004-04-09 2005-04-08 Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin

Publications (2)

Publication Number Publication Date
EA200601651A1 true EA200601651A1 (ru) 2007-02-27
EA010166B1 EA010166B1 (ru) 2008-06-30

Family

ID=34963800

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601651A EA010166B1 (ru) 2004-04-09 2005-04-08 Полиморфные формы трет-бутилового эфира аторвастатина и их использование в качестве промежуточных соединений для получения аторвастатина

Country Status (15)

Country Link
EP (1) EP1732886B1 (ru)
CN (2) CN101538238B (ru)
AT (1) ATE459602T1 (ru)
DE (1) DE602005019703D1 (ru)
DK (1) DK1732886T3 (ru)
EA (1) EA010166B1 (ru)
ES (1) ES2339570T3 (ru)
HR (1) HRP20100217T1 (ru)
NO (1) NO20065146L (ru)
PL (1) PL1732886T3 (ru)
PT (1) PT1732886E (ru)
RS (1) RS51259B (ru)
SI (2) SI21745A (ru)
UA (1) UA86059C2 (ru)
WO (1) WO2005097742A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
WO2009023260A2 (en) * 2007-08-15 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for synthesis of pyrrole derivative, an intermediate for atorvastatin
CN101560177B (zh) * 2008-04-16 2012-10-03 北京万全阳光医学技术有限公司 一种阿托伐他汀钙的制备方法
SI2413911T1 (sl) 2009-03-31 2014-04-30 Krka, D.D., Novo Mesto Progresivna emulzijska kristalizacija
CN105693587A (zh) * 2016-01-15 2016-06-22 安徽悦康凯悦制药有限公司 一种阿托伐他汀钙的生产工艺
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PL362981A1 (en) * 2000-11-16 2004-11-02 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
NZ529913A (en) * 2001-08-16 2005-03-24 Teva Pharma Processes for preparing calcium salt forms of statins

Also Published As

Publication number Publication date
RS51259B (sr) 2010-12-31
DK1732886T3 (da) 2010-06-14
CN101538238B (zh) 2012-08-29
SI1732886T1 (sl) 2010-06-30
EP1732886A1 (en) 2006-12-20
SI21745A (sl) 2005-10-31
PL1732886T3 (pl) 2010-08-31
ES2339570T3 (es) 2010-05-21
ATE459602T1 (de) 2010-03-15
UA86059C2 (ru) 2009-03-25
WO2005097742A1 (en) 2005-10-20
HRP20100217T1 (hr) 2010-05-31
CN1946687A (zh) 2007-04-11
CN1946687B (zh) 2011-09-28
EA010166B1 (ru) 2008-06-30
PT1732886E (pt) 2010-03-12
DE602005019703D1 (de) 2010-04-15
NO20065146L (no) 2006-11-08
CN101538238A (zh) 2009-09-23
EP1732886B1 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
EA200601651A1 (ru) Полиморфные формы трет-бутилового эфира аторвастатина и их использование в качестве промежуточных соединений для получения аторвастатина
WO2003086306A3 (en) 5ht2c receptor modulators
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA201200794A1 (ru) Триазолопиридины
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
NO20075809L (no) DNA-PK inhibitorer
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
HU0400405D0 (en) Novel compounds
TW200734311A (en) New compounds
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
WO2006021213A3 (en) Vasopressin v1a antagonists
MX2007007845A (es) Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento.
SE0300119D0 (sv) Novel compounds
GT200500296A (es) Sintesis asimetrica de derivados del dehidrobenzofurano
CY1109055T1 (el) 11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
ES2311803T3 (es) Composiciones embolicas de silicie pirogena.
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
EA200700673A1 (ru) Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
HK1080088A1 (zh) 製備c-7取代的5-雄甾烯的方法
MXPA03006605A (es) Esteres de indol-5-ilo del acido bencensulfonico como antagonistas del receptor 5-ht6.
WO2005075467A3 (en) Crystalline forms of zolmitriptan

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU